187 related articles for article (PubMed ID: 23300762)
1. Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression.
Barbone D; Cheung P; Battula S; Busacca S; Gray SG; Longley DB; Bueno R; Sugarbaker DJ; Fennell DA; Broaddus VC
PLoS One; 2012; 7(12):e52753. PubMed ID: 23300762
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
Premkumar DR; Jane EP; Agostino NR; DiDomenico JD; Pollack IF
Mol Carcinog; 2013 Feb; 52(2):118-33. PubMed ID: 22086447
[TBL] [Abstract][Full Text] [Related]
3. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
[TBL] [Abstract][Full Text] [Related]
4. The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance.
Barbone D; Ryan JA; Kolhatkar N; Chacko AD; Jablons DM; Sugarbaker DJ; Bueno R; Letai AG; Coussens LM; Fennell DA; Broaddus VC
Cell Death Dis; 2011 Jun; 2(6):e174. PubMed ID: 21697949
[TBL] [Abstract][Full Text] [Related]
5. Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids.
Yang TM; Barbone D; Fennell DA; Broaddus VC
Am J Respir Cell Mol Biol; 2009 Jul; 41(1):14-23. PubMed ID: 19097992
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.
Li C; Li R; Grandis JR; Johnson DE
Mol Cancer Ther; 2008 Jun; 7(6):1647-55. PubMed ID: 18566236
[TBL] [Abstract][Full Text] [Related]
7. The anti-apoptotic protein BCL2L1/Bcl-xL is neutralized by pro-apoptotic PMAIP1/Noxa in neuroblastoma, thereby determining bortezomib sensitivity independent of prosurvival MCL1 expression.
Hagenbuchner J; Ausserlechner MJ; Porto V; David R; Meister B; Bodner M; Villunger A; Geiger K; Obexer P
J Biol Chem; 2010 Mar; 285(10):6904-12. PubMed ID: 20051518
[TBL] [Abstract][Full Text] [Related]
8. Characterization of bortezomib-adapted I-45 mesothelioma cells.
Zhang L; Littlejohn JE; Cui Y; Cao X; Peddaboina C; Smythe WR
Mol Cancer; 2010 May; 9():110. PubMed ID: 20482802
[TBL] [Abstract][Full Text] [Related]
9. BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma.
Busacca S; Chacko AD; Klabatsa A; Arthur K; Sheaff M; Barbone D; Mutti L; Gunasekharan VK; Gorski JJ; El-Tanani M; Broaddus VC; Gaudino G; Fennell DA
PLoS One; 2013; 8(6):e65489. PubMed ID: 23762382
[TBL] [Abstract][Full Text] [Related]
10. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.
Nikrad M; Johnson T; Puthalalath H; Coultas L; Adams J; Kraft AS
Mol Cancer Ther; 2005 Mar; 4(3):443-9. PubMed ID: 15767553
[TBL] [Abstract][Full Text] [Related]
11. Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Zang Y; Kirk CJ; Johnson DE
Cancer Biol Ther; 2014 Sep; 15(9):1142-52. PubMed ID: 24915039
[TBL] [Abstract][Full Text] [Related]
12. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.
Pérez-Galán P; Roué G; Villamor N; Campo E; Colomer D
Blood; 2007 May; 109(10):4441-9. PubMed ID: 17227835
[TBL] [Abstract][Full Text] [Related]
13. Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells.
Smith AJ; Dai H; Correia C; Takahashi R; Lee SH; Schmitz I; Kaufmann SH
J Biol Chem; 2011 May; 286(20):17682-92. PubMed ID: 21454712
[TBL] [Abstract][Full Text] [Related]
14. Enhanced apoptosis by pemetrexed and simvastatin in malignant mesothelioma and lung cancer cells by reactive oxygen species-dependent mitochondrial dysfunction and Bim induction.
Hwang KE; Kim YS; Hwang YR; Kwon SJ; Park DS; Cha BK; Kim BR; Yoon KH; Jeong ET; Kim HR
Int J Oncol; 2014 Oct; 45(4):1769-77. PubMed ID: 25096993
[TBL] [Abstract][Full Text] [Related]
15. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA.
Nawrocki ST; Carew JS; Maclean KH; Courage JF; Huang P; Houghton JA; Cleveland JL; Giles FJ; McConkey DJ
Blood; 2008 Oct; 112(7):2917-26. PubMed ID: 18641367
[TBL] [Abstract][Full Text] [Related]
16. A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis.
Chen S; Zhang Y; Zhou L; Leng Y; Lin H; Kmieciak M; Pei XY; Jones R; Orlowski RZ; Dai Y; Grant S
Blood; 2014 Oct; 124(17):2687-97. PubMed ID: 25208888
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.
Dai Y; Chen S; Wang L; Pei XY; Kramer LB; Dent P; Grant S
Br J Haematol; 2011 Apr; 153(2):222-35. PubMed ID: 21375523
[TBL] [Abstract][Full Text] [Related]
18. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1.
Chen S; Dai Y; Pei XY; Grant S
Mol Cell Biol; 2009 Dec; 29(23):6149-69. PubMed ID: 19805519
[TBL] [Abstract][Full Text] [Related]
19. Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma.
Kunami N; Katsuya H; Nogami R; Ishitsuka K; Tamura K
Anticancer Res; 2014 Oct; 34(10):5287-94. PubMed ID: 25275021
[TBL] [Abstract][Full Text] [Related]
20. MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib.
Wirth M; Stojanovic N; Christian J; Paul MC; Stauber RH; Schmid RM; Häcker G; Krämer OH; Saur D; Schneider G
Nucleic Acids Res; 2014; 42(16):10433-47. PubMed ID: 25147211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
